Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Jazz Pharmaceuticals Ireland Limited has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 3 distinct examiners and 2 distinct art units. With 3 examiners for 3 actions, each of the company's current matters in this technology area is receiving an independent review from a different individual at the patent office.
PAK, YONG D is the busiest examiner for the company, with 1 pending office action. The distribution across 2 distinct art units indicates that the company's biotechnology work is being reviewed by more than one specialized department. This structure requires managing 3 different examiner personalities while adhering to the standards of 2 different art units. The parity between the 3 pending office actions and 3 distinct examiners ensures that no single examiner has an outsized influence on the company's current portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, YONG D | 1 | 74.6% | +14.3% |
| PAGUIO FRISING, MICHELLE F | 1 | 71.1% | +39.3% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18880475 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | PAK, YONG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16767920 | METHODS OF TREATMENT WITH ASPARAGINASE | ROBINSON, HOPE A | 34d |
| 18880475 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | PAK, YONG D | — |
| 18285209 | FORMULATIONS OF L-ASPARAGINASE | PAGUIO FRISING, MICHELLE F | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18880475 | COMBINATION THERAPIES INVOLVING L-ASPARAGINASE | PAK, YONG D | — | §102§103§112 | Non-Final OA | — | Pending | Dec 31, 2024 |
| 18285209 | FORMULATIONS OF L-ASPARAGINASE | PAGUIO FRISING, MICHELLE F | 1651 | §102 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 16767920 | METHODS OF TREATMENT WITH ASPARAGINASE | ROBINSON, HOPE A | 1652 | §103 | Non-Final OA | 34d | Pending | May 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial